Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

Inclusion Criteria: * Informed consent written, signed (or with a cross) and dated * Men aged 18 to 65 included (women not included in the study) * Microfilarial density between 1 and 1,000 mf/mL * body weight ≥ 45 kg and less than 85 kg * Good general condition, as determined by the medical questionnaire and clinical examination * Hematological parameters and adequate renal and hepatic functions, such as: * Leukocytes ≥ 2,800 and ≤ 11,300 cells/mL * Hemoglobin ≥ 10.0 g/dL * Platelets ≥100,000/mm3 * Serum creatinine ≤ 2.5 upper limit (UL) of the laboratory * Total bilirubinemia ≤ 2.5 x UL * ALAT ≤ 2.5 x UL * Negative urinary strip: absence of leucocyturia, hematuria, and proteinuria (in case of positivity, a second urinary strip test will be made, for confirmation) Exclusion Criteria: * Participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of MOX-2 mg or IVM). * Person who has taken IVM in the last 6 months * Any vaccination in the 4 weeks preceding this study * Acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ENT, digestive, cutaneous, with implementation of an antibiotic treatment or not) * Long-term antiretroviral therapy (protease inhibitor, non-nucleoside reverse transcriptase inhibitor), or treatment with ampicillin or chloramphenicol within 10 d…